Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefurulimab versus placebo in adults with AChR-positive generalized myasthenia gravis
NL-OMON59290Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Gefurulimab with Placebo (2 arms). Primary endpoint: Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26. Started Dec 2023; status: completed.
02
Drugs
gefurulimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON59290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59290.